Subscription Center
Apr 16, 2009 02:45 PM
Pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer said today that they're creating a company dedicated to developing HIV medications. The unusual arrangement will give London-based GSK 85 percent equity and New York's Pfizer the remainder.
The companies said in a statement that the merger would "be more sustainable and broader in scope than either company's individually," giving the new partnership 19 percent of the HIV drug market through a combined portfolio of 11 already-available meds and six candidates in development. The idea is that the $2.4 billion in sales generated from the marketed drugs will keep the development pipeline moving, the companies said.
GSK's vaccine development won't be part of the new company, according to Bloomberg News.
The deal helps GSK because its HIV drugs are old (and approaching patent expiration) and its own development pipeline is thin, the Wall Street Journal notes. Pfizer, on the other hand, has more robust drug candidates but fewer meds on the market, according to the Associated Press.
Still, Gilead Sciences, based in Foster City, Calif., now dominates the HIV drug market.
"We continue expect Gilead to remain a step ahead of the competition and view the new company as another example of a pharma merger driven by weakness," M. Ian Somaiya, an analyst at Thomas Weisel Partners, wrote in a note to clients, Bloomberg News notes.
Image © iStockphoto/rocksunderwater
Tags:
vaccines,
drugs,
AIDS,
HIV
More News Blog:
Next: Spammers be damned: Junk e-mail is a huge waste of energy
Previous: High-speed rail getting on track in the U.S.
See what we're tweeting about
FlyingTrilobite .@edyong209 @Sci_Phile We often take heat @Symbiartic as irrelevant popcult nonsense degrading SA name. I <3 challenging what #scicomm is.
Myrmecos Recipe for a Photograph #2: Bee in Flight | Compound Eye http://t.co/s5JuowiF5H via @sciam FlyingTrilobite I like the dinosaurs on this Avengers cover! Nice one, @mikedeodato ! #sciart http://t.co/40UlDISPE8
Deadline: Jun 30 2013
Reward: $1,000,000 USD
This is a Reduction-to-Practice Challenge that requires written documentation and&
Deadline: Aug 31 2013
Reward: $100,000 USD
The Geoffrey Beene Foundation Alzheimer’s Initiative (GBFAI) is launching the 2013 Geoffrey Beene Global NeuroDiscovery Challenge whose
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
Comments
Add Comment